422 related articles for article (PubMed ID: 31806642)
21. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.
Reade CJ; McVey RM; Tone AA; Finlayson SJ; McAlpine JN; Fung-Kee-Fung M; Ferguson SE
J Obstet Gynaecol Can; 2014 Feb; 36(2):133-140. PubMed ID: 24518912
[TBL] [Abstract][Full Text] [Related]
22. CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.
Walton JB; Farquharson M; Mason S; Port J; Kruspig B; Dowson S; Stevenson D; Murphy D; Matzuk M; Kim J; Coffelt S; Blyth K; McNeish IA
Sci Rep; 2017 Dec; 7(1):16827. PubMed ID: 29203787
[TBL] [Abstract][Full Text] [Related]
23. Methylomic Landscapes of Ovarian Cancer Precursor Lesions.
Pisanic TR; Wang Y; Sun H; Considine M; Li L; Wang TH; Wang TL; Shih IM
Clin Cancer Res; 2020 Dec; 26(23):6310-6320. PubMed ID: 32817081
[TBL] [Abstract][Full Text] [Related]
24. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.
Sherman-Baust CA; Kuhn E; Valle BL; Shih IeM; Kurman RJ; Wang TL; Amano T; Ko MS; Miyoshi I; Araki Y; Lehrmann E; Zhang Y; Becker KG; Morin PJ
J Pathol; 2014 Jul; 233(3):228-37. PubMed ID: 24652535
[TBL] [Abstract][Full Text] [Related]
25. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
Škapa P; Dundr P
Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
[TBL] [Abstract][Full Text] [Related]
26.
Saini U; Suarez AA; Naidu S; Wallbillich JJ; Bixel K; Wanner RA; Bice J; Kladney RD; Lester J; Karlan BY; Goodfellow PJ; Cohn DE; Selvendiran K
Cancer Res; 2018 Apr; 78(7):1739-1750. PubMed ID: 29339537
[TBL] [Abstract][Full Text] [Related]
27. Protocol for the Detection of Organoid-Initiating Cell Activity in Patient-Derived Single Fallopian Tube Epithelial Cells.
Feng L; Yang W; Zhao H; Bakkum-Gamez J; Sherman ME; Kannan N
Methods Mol Biol; 2022; 2429():445-454. PubMed ID: 35507180
[TBL] [Abstract][Full Text] [Related]
28. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis.
Kuhn E; Meeker A; Wang TL; Sehdev AS; Kurman RJ; Shih IeM
Am J Surg Pathol; 2010 Jun; 34(6):829-36. PubMed ID: 20431479
[TBL] [Abstract][Full Text] [Related]
29. Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern.
Kim HN; Woo HY; DO SI; Kim HS
In Vivo; 2019; 33(5):1485-1492. PubMed ID: 31471396
[TBL] [Abstract][Full Text] [Related]
30. The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice.
Kim J; Coffey DM; Ma L; Matzuk MM
Endocrinology; 2015 Jun; 156(6):1975-81. PubMed ID: 25815421
[TBL] [Abstract][Full Text] [Related]
31. Tubal origin of ovarian cancer - the double-edged sword of haemoglobin.
Lin SF; Gerry E; Shih IM
J Pathol; 2017 May; 242(1):3-6. PubMed ID: 28054715
[TBL] [Abstract][Full Text] [Related]
32. Cell Origins of High-Grade Serous Ovarian Cancer.
Kim J; Park EY; Kim O; Schilder JM; Coffey DM; Cho CH; Bast RC
Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30424539
[TBL] [Abstract][Full Text] [Related]
33. Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.
Köbel M; Yang RZ; Kang EY; Al-Shamma Z; Cook LS; Kinloch M; Carey MS; Hopkins L; Nelson GS; McManus KJ; Vizeacoumar FS; Vizeacoumar FJ; Freywald A; Fu Y; Reuss DE; Lee CH
Gynecol Oncol; 2023 Nov; 178():80-88. PubMed ID: 37820398
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
Chay WY; McCluggage WG; Lee CH; Köbel M; Irving J; Millar J; Gilks CB; Tinker AV
Int J Gynecol Cancer; 2016 Mar; 26(3):431-6. PubMed ID: 26807643
[TBL] [Abstract][Full Text] [Related]
35. Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis.
Wang Y; Huang P; Wang BG; Murdock T; Cope L; Hsu FC; Wang TL; Shih IM
Cancer Res; 2022 Dec; 82(24):4528-4541. PubMed ID: 36206311
[TBL] [Abstract][Full Text] [Related]
36. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.
Kuhn E; Kurman RJ; Vang R; Sehdev AS; Han G; Soslow R; Wang TL; Shih IeM
J Pathol; 2012 Feb; 226(3):421-6. PubMed ID: 21990067
[TBL] [Abstract][Full Text] [Related]
37. Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention.
Yoon JY; Chapel DB; Goebel E; Qian X; Mito JK; Horowitz NS; Miron A; Soong TR; Xian W; Crum CP
J Pathol; 2022 Jul; 257(3):255-261. PubMed ID: 35238033
[TBL] [Abstract][Full Text] [Related]
38. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.
Bashashati A; Ha G; Tone A; Ding J; Prentice LM; Roth A; Rosner J; Shumansky K; Kalloger S; Senz J; Yang W; McConechy M; Melnyk N; Anglesio M; Luk MT; Tse K; Zeng T; Moore R; Zhao Y; Marra MA; Gilks B; Yip S; Huntsman DG; McAlpine JN; Shah SP
J Pathol; 2013 Sep; 231(1):21-34. PubMed ID: 23780408
[TBL] [Abstract][Full Text] [Related]
39. High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression.
Roh MH; Yassin Y; Miron A; Mehra KK; Mehrad M; Monte NM; Mutter GL; Nucci MR; Ning G; Mckeon FD; Hirsch MS; Wa X; Crum CP
Mod Pathol; 2010 Oct; 23(10):1316-24. PubMed ID: 20562848
[TBL] [Abstract][Full Text] [Related]
40. PTEN Deficiency in Tubo-Ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification.
Zhang X; Wang A; Han L; Liang B; Allard G; Diver E; Howitt BE
Mod Pathol; 2023 May; 36(5):100106. PubMed ID: 36805789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
